They should separate operational care access from research access and make consent, anonymisation and purpose limitation explicit in the governance flow. Research use changes the risk profile because the data may be repurposed over time, even when it is not duplicated across systems. Identity controls still need to enforce who can approve and use it.
Why research reuse changes the security decision
Once patient data is reused for research, the control question shifts from routine operational access to governed secondary use. That means the security team has to treat the dataset as something with a different purpose, different approval path, and different exposure profile. The key issue is not only who can see the record, but who can authorise the research purpose, under what conditions, and with what evidence.
Purpose limitation matters because research use often expands over time. A dataset may start with a narrow study, then be reused for a different protocol, combined with other records, or retained longer than the original operational need. Security controls have to follow that change in purpose rather than assuming the original care workflow still applies.
Identity controls still matter at this layer because approval rights, access entitlements, and exceptions should be explicit. The practical question is whether the people or systems approving research use are constrained to the approved purpose, or whether they can silently extend access into broader operational or analytical use.
How to separate care access from research access
The cleanest pattern is to keep care access and research access in distinct workflows, even when they draw from the same source data. Operational users should retain access only for treatment, billing, and care coordination, while research users should work from a governed route that records the protocol, approval, and permitted data fields. That separation reduces the chance that a legitimate care credential becomes a shortcut into secondary use.
Where possible, teams should use different approval points, different access roles, and different audit expectations for the two purposes. If the same platform serves both, the policy boundary still has to be visible in configuration and logging, otherwise the organization loses the ability to prove which use was authorised. This is especially important when datasets move between clinical, analytics, and study environments.
For broader governance, the research workflow should make it obvious whether the data is identifiable, pseudonymised, or anonymised, because each state changes both privacy exposure and downstream handling. A study that claims to need identifiable data should face tighter review than one that can operate on a minimised or de-identified extract.
What security teams should verify before approving reuse
Security teams should verify that the research request has an explicit purpose, a valid approval trail, and a clear data-minimisation decision. They should also verify that retention, sharing, and recontact rules are defined before access is granted, not negotiated after researchers already have the data. Where consent is part of the governance model, the consent scope should match the intended research use rather than being treated as a blanket permission.
It is also worth checking whether the request can be satisfied with anonymised data, a limited extract, or a controlled enclave instead of broad export. That decision is often more important than the delivery mechanism itself, because the main risk comes from unnecessary exposure and reuse, not from the mere existence of a research project.
When access is justified, the team should require auditability for the entire path: who approved the study, who accessed the records, what fields were exposed, and when the access expires. If those answers are not available, the control is too weak to support secondary use with confidence.
Risk and Threat Considerations
Research reuse increases the likelihood of purpose drift, overcollection, and longer retention than the original care case required. That creates privacy and governance risk even when the same records are not copied into a new system, because the exposure changes once the data can be repurposed, combined, or retained under a broader justification.
Failure mechanism: The failure is usually weak separation between care authorisation and research authorisation, combined with vague consent language or incomplete anonymisation decisions. That allows a legitimate access path to be reused for a different purpose without a clear control boundary.
Impact: The result can be unauthorised secondary use, loss of purpose limitation, difficult audit reconstruction, and higher harm if sensitive clinical data is exposed beyond the original treatment context.
Standards & Framework Alignment
This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.
NIST SP 800-53 Rev 5 sets the technical controls, while GDPR and ISO/IEC 27001:2022 define the regulatory obligations.
| Framework | Control / Reference | Relevance |
|---|---|---|
| GDPR | Article 5 — Principles relating to processing of personal data | Patient-data research reuse hinges on purpose limitation and minimisation. |
| Article 25 — Data protection by design and by default | Secondary-use workflows need built-in separation between care and research access. | |
| Article 9 — Processing of special categories of personal data | Patient data commonly includes health data, which needs stricter handling for research reuse. | |
| Recommendation — Apply Article 5 principles to limit research use to the stated purpose and minimum necessary data. Design access paths so research use is separated from operational care by default. Apply the stricter Article 9 conditions before allowing health data into research workflows. | ||
| NIST SP 800-53 Rev 5 | AC-6 — Least Privilege | Research access should be narrower than operational care access. |
| IA-5 — Authenticator Management | Research workflows still depend on controlling credentials and exceptions for access. | |
| AU-2 — Event Logging | Secondary use requires evidence of who approved, accessed, and exported the data. | |
| Recommendation — Restrict research access to the minimum set of approvals and records needed for the study. Manage credentials and access lifecycles so research approval paths stay explicit and time-bound. Log research approval, access, and export events so secondary use remains auditable. | ||
| ISO/IEC 27001:2022 | A.5.12 — Classification of information | Research reuse depends on classifying patient data and its authorised use state. |
| A.5.15 — Access control | Care and research access need distinct authorisation boundaries. | |
| A.5.34 — Privacy and protection of PII | Patient-data reuse is a privacy-sensitive handling decision. | |
| Recommendation — Classify patient data for care and research handling so controls match the use case. Separate care and research access rules so permissions reflect the approved purpose. Apply privacy controls that limit secondary use, sharing, and retention of patient data. | ||
Practitioner Guidance
Decision rule: If the research team needs identifiable or linkable data, treat the request as a higher-risk exception and require stronger approval, narrower access, and explicit expiry. If the study can be satisfied with anonymised or heavily minimised data, prefer that route first and document why the stronger protection is sufficient.
What to verify: Confirm that the access model, consent scope, and retention period all align to the same research purpose. The common mistake is to approve the study based on ethics review alone and assume security can be handled later; by then, the exposure boundary is already set.
Practitioner takeaway: Good control here is not about blocking research, it is about making the secondary-use boundary visible, enforceable, and auditable so care access does not quietly become research access.
Related resources from NHI Mgmt Group
Deepen Your Knowledge
Free weekly newsletter
Subscribe to the NHI & AI Identity Journal
The latest on NHI and Agentic AI security – articles, research, breaches, news and events every week.
Bonus 33% off our NHI Course when you subscribe.
Reviewed and updated by the NHIMG editorial team on October 8, 2026.
NHI Mgmt Group — the #1 independent authority on Non-Human Identity, IAM, and Agentic AI security. nhimg.org